For decades, a diagnosis of Huntington’s disease has meant facing unrelenting decline with no cure or successful treatment in sight. Now, a groundbreaking discovery may finally offer what patients and caregivers have long been waiting for: hope. Could this be the momentum shift needed to change the tides of neurodegenerative disease from incurable to manageable?
Huntington’s disease is a devastating inherited condition that disrupts movement, thinking and mood. It typically appears between the ages of 30 and 50, increasing the risk of being passed on to children. The cause lies in a genetic mutation in the Huntingtin (HTT) gene, where a section of DNA known as CAG repeats is copied too many times. These excessive repeats make the gene produce a toxic protein that damages neurons in the brain; the more repeats, the earlier and the more severe the onset.
Symptoms usually begin subtly, with memory lapses, concentration problems, and mood changes. As the disease progresses, movement becomes clumsy or jerky, and patients may experience muscle stiffness, speech difficulties and profound behaviour changes such as apathy or psychosis. Over 10-20 years, these symptoms slowly worsen until complications, unfortunately, become fatal.
Historically, this was the route the disease would take; a diagnosis would mean a definitive journey down this path. Until recently, treatment options were limited to drugs that could only ease symptoms, such as controlling involuntary movement or managing depression, alongside supportive therapies like physiotherapy or counselling. None, however, successfully addressed the underlying genetic cause. This is the current fate of approximately 75,000 people living with Huntington’s in Europe and the US, and hundreds of thousands of people who are carrying the mutation, which will inevitably develop into the disease.
But is this still the case? Researchers have developed a potential gene therapy called AMT-130, created by researchers at uniQure, which directly targets the disease at its source. The treatment works by ‘silencing’ the huntingtin [HTT] gene, both the healthy and the unhealthy mutant versions. The therapy introduces a new gene into two main brain areas affected by Huntington’s, the putamen and caudate nucleus, via a one-time surgical procedure. As the procedure affects all protein production in the huntingtin genes, it reduces the overall production in a controlled and partial way, without eliminating the essential healthy huntingtin protein. This has resulted in researchers striking a balance between therapy and safety; early clinical trial data for patients receiving a high dose of AMT-130 showed around 75% less disease progression over three years, compared to controls. In other words? AMT-130 is a monumental breakthrough, acting as the only therapy shown to make Huntington’s manageable.
The treatment is still in its early stages, with trials so far limited to people aged 25-65 who have early-stage Huntington’s disease and a confirmed CAG repeat count of above 40. To ensure reliable results, researchers selected participants with specific characteristics, such as maintained striatal volume, while excluding patients with complicating medical histories, including past infections, severe allergies, or previous experimental treatments.
For the Huntington’s community, this breakthrough offers more than scientific progress; it provides hope. If further trials confirm its safety and effectiveness, AMT-130 could mark the beginning of a new era, one where Huntington’s disease is not a sentence, but a condition that can finally be managed.